Receptor-specific Targeting with Liposomes in Vitro Based on Sterol-PEG(1300) Anchors

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2008 Nov 19

PMID 19015959

Citations 10

Authors

Markus Gantert

Felicitas Lewrick

Joanna E Adrian

Jochen Rossler

Thomas Steenpass

Rolf Schubert

Regine Peschka-Suss

Affiliations

Soon will be listed here.

Abstract

Purpose: The challenge in developing liposomes to be used in active drug targeting is to design a method that can be used for modifying liposomal membranes that is applicable for a number of different specific ligands. In this study, the post insertion technique was used with activated sterol-PEG(1300) anchors and was evaluated with regard to its effectiveness in active targeting in vitro. The key advantage of these anchors is that the insertion step into the liposomal membrane takes place at room temperature and is very fast.

Materials And Methods: For in vitro experiments, neuroblastoma cell lines overexpressing GD2 antigen on their surface as a target structure were chosen. This allowed the use of anti-GD2 antibodies coupled to the liposomal surface for testing of specific binding. These modified liposomes were labelled with rhodamine-PE and their cellular association was analyzed by flow cytometry.

Results: It was shown that the activated sterol-PEG(1300) anchors allow specific and significant interactions of the modified liposomes with GD2 positive cells.

Conclusion: Coupling using sterol-PEG(1300) anchors is both simple and rapid. It is reproducible and applicable for all ligands bearing amino groups. This method demonstrates the advantage of a ready-to-use system for the modification of pre-formed liposomes with different ligands.

Citing Articles

Improving Cancer Targeting: A Study on the Effect of Dual-Ligand Density on Targeting of Cells Having Differential Expression of Target Biomarkers.

Sultana N, David A Int J Mol Sci. 2023; 24(17).

PMID: 37685852 PMC: 10487485. DOI: 10.3390/ijms241713048.

Multi-targeted H/F MRI unmasks specific danger patterns for emerging cardiovascular disorders.

Flogel U, Temme S, Jacoby C, Oerther T, Keul P, Flocke V Nat Commun. 2021; 12(1):5847.

PMID: 34615876 PMC: 8494909. DOI: 10.1038/s41467-021-26146-6.

MRI-based molecular imaging of epicardium-derived stromal cells (EpiSC) by peptide-mediated active targeting.

Straub T, Nave J, Bouvain P, Akbarzadeh M, Dasa S, Kistner J Sci Rep. 2020; 10(1):21669.

PMID: 33303866 PMC: 7728754. DOI: 10.1038/s41598-020-78600-y.

Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.

Jakoby J, Beuschlein F, Mentz S, Hantel C, Suss R Oncotarget. 2015; 6(41):43698-711.

PMID: 26497207 PMC: 4791260. DOI: 10.18632/oncotarget.6191.

Physical chemistry of nanomedicine: understanding the complex behaviors of nanoparticles in vivo.

Lane L, Qian X, Smith A, Nie S Annu Rev Phys Chem. 2015; 66:521-47.

PMID: 25622189 PMC: 8590374. DOI: 10.1146/annurev-physchem-040513-103718.

References

Allen T, Brandeis E, Hansen C, Kao G, Zalipsky S . A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta. 1995; 1237(2):99-108. DOI: 10.1016/0005-2736(95)00085-h. View

Park J, Hong K, Kirpotin D, Colbern G, Shalaby R, Baselga J . Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002; 8(4):1172-81. View

Takasaki J, Ansell S . Micelles as intermediates in the preparation of protein-liposome conjugates. Bioconjug Chem. 2006; 17(2):438-50. DOI: 10.1021/bc050051r. View

Metelitsa L, Gillies S, Super M, Shimada H, Reynolds C, Seeger R . Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and.... Blood. 2002; 99(11):4166-73. DOI: 10.1182/blood.v99.11.4166. View

Delgado C, Patel J, FRANCIS G, Fisher D . Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem. 1990; 12(2):119-28. View

Tajima K, GERSHFELD N . Equilibrium studies of lecithin-cholesterol interactions. II. Phase relations in surface films: analysis of the "condensing" effect of cholesterol. Biophys J. 1978; 22(3):489-500. PMC: 1473480. DOI: 10.1016/S0006-3495(78)85501-5. View

Kirpotin D, Park J, Hong K, Zalipsky S, Li W, Carter P . Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997; 36(1):66-75. DOI: 10.1021/bi962148u. View

Loughrey H, Wong K, Choi L, Cullis P, Bally M . Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta. 1990; 1028(1):73-81. DOI: 10.1016/0005-2736(90)90267-r. View

Iden D, Allen T . In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta. 2001; 1513(2):207-16. DOI: 10.1016/s0005-2736(01)00357-1. View

10.

Hansen C, Kao G, Moase E, Zalipsky S, Allen T . Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta. 1995; 1239(2):133-44. DOI: 10.1016/0005-2736(95)00138-s. View

11.

Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D . Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res. 2003; 9(12):4595-605. View

12.

Tseng Y, Hong R, Tao M, Chang F . Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer. 1999; 80(5):723-30. DOI: 10.1002/(sici)1097-0215(19990301)80:5<723::aid-ijc16>3.0.co;2-l. View

13.

Metselaar J, Mastrobattista E, Storm G . Liposomes for intravenous drug targeting: design and applications. Mini Rev Med Chem. 2002; 2(4):319-29. DOI: 10.2174/1389557023405873. View

14.

Harasym T, Tardi P, Longman S, Ansell S, Bally M, Cullis P . Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem. 1995; 6(2):187-94. DOI: 10.1021/bc00032a006. View

15.

Huang C, Yu A . Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother. 1995; 41(6):331-8. PMC: 11037673. DOI: 10.1007/BF01526552. View

16.

Yuda T, Maruyama K, IWATSURU M . Prolongation of liposome circulation time by various derivatives of polyethyleneglycols. Biol Pharm Bull. 1996; 19(10):1347-51. DOI: 10.1248/bpb.19.1347. View

17.

Pagnan G, Montaldo P, Pastorino F, Raffaghello L, Kirchmeier M, Allen T . GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer. 1999; 81(2):268-74. DOI: 10.1002/(sici)1097-0215(19990412)81:2<268::aid-ijc17>3.0.co;2-1. View

18.

Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U . Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm. 1999; 181(1):79-93. DOI: 10.1016/s0378-5173(99)00002-2. View

19.

Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A . Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol. 2001; 51(1):11-8. DOI: 10.1023/a:1006420200626. View

20.

Tardi , Bally , Harasym . Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev. 2000; 32(1-2):99-118. DOI: 10.1016/s0169-409x(97)00134-8. View